Forschung Sektion Translationale… Publikationen



Budczies, J., Kirchner, M., Kluck, K., Kazdal, D., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J., Winter, H., Meister, M., Muley, T., Goldmann, T., Fröhling, S., Wermke, M., Waller, C. F., Tufman, A., Reck, M., Peters, S., … Stenzinger, A. (2022). Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma. Cancer Immunology, Immunotherapy, 71(2), 251–265.

Laplana, M., Bieg, M., Faltus, C., Melnik, S., Bogatyrova, O., Gu, Z., Muley, T., Meister, M., Dienemann, H., Herpel, E., Amos, C. I., Schlesner, M., Eils, R., Plass, C., & Risch, A. (2022). Differentially methylated regions within lung cancer risk loci are enriched in deregulated enhancers. Epigenetics, 17(2), 117–132.

Schneider, M. A., Rozy, A., Wrenger, S., Christopoulos, P., Muley, T., Thomas, M., Meister, M., Welte, T., Chorostowska-Wynimko, J., & Janciauskiene, S. (2022). Acute Phase Proteins as Early Predictors for Immunotherapy Response in Advanced NSCLC: An Explorative Study. Frontiers in Oncology, 12.

SCHNEIDER, M. A., Richtmann, S., GRÜNDING, A. R., Wrenger, S., Welte, T., Meister, M., Kriegsmann, M., Winter, H., Muley, T., & Janciauskiene, S. (2022). Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma. International Journal of Oncology, 60(4), 39.

Salgueiro, L., Kummer, S., Sonntag-Buck, V., Weiß, A., Schneider, M. A., Kräusslich, H.-G., & Sotillo, R. (2022). Generation of Human Lung Organoid Cultures from Healthy and Tumor Tissue to Study Infectious Diseases. Journal of Virology, 96(7).

Theobald, V., Benjamin, N., Seyfarth, H. J., Halank, M., Schneider, M. A., Richtmann, S., Hinderhofer, K., Xanthouli, P., Egenlauf, B., Seeger, R., Hoeper, M. M., Jonigk, D., Grünig, E., & Eichstaedt, C. A. (2022). Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity? Genes, 13(5), 759.

Yaung, S. J., Woestmann, C., Ju, C., Ma, X. M., Gattam, S., Zhou, Y., Xi, L., Pal, S., Balasubramanyam, A., Tikoo, N., Heussel, C. P., Thomas, M., Kriegsmann, M., Meister, M., Schneider, M. A., Herth, F. J., Wehnl, B., Diehn, M., Alizadeh, A. A., … Muley, T. (2022). Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA. Cancers, 14(10), 2479.

Bühler, L., Enderle, M. D., Kahn, N., Polke, M., Schneider, M. A., Heußel, C. P., Herth, F. J. F., & Linzenbold, W. (2022). Establishment of a Tissue-Mimicking Surrogate for Pulmonary Lesions to Improve the Development of RFA Instruments and Algorithms. Biomedicines, 10(5), 1100.

Stögbauer, F., Lautizi, M., Kriegsmann, M., Winter, H., Muley, T., Kriegsmann, K., Jesinghaus, M., Baumbach, J., Schüffler, P., Weichert, W., Kacprowski, T., & Boxberg, M. (2022). Tumour cell budding and spread through air spaces in squamous cell carcinoma of the lung – Determination and validation of optimal prognostic cut-offs. Lung Cancer, 169, 1–12.

Janßen, C., Boskamp, T., Hauberg-Lotte, L., Behrmann, J., Deininger, S. O., Kriegsmann, M., Kriegsmann, K., Steinbuß, G., Winter, H., Muley, T., Casadonte, R., Kriegsmann, J., & Maaß, P. (2022). Robust subtyping of non-small cell lung cancer whole sections through MALDI mass spectrometry imaging. Proteomics - Clinical Applications, 16(4), 2100068.

Rajakumar, T., Horos, R., Jehn, J., Schenz, J., Muley, T., Pelea, O., Hofmann, S., Kittner, P., Kahraman, M., Heuvelman, M., Sikosek, T., Feufel, J., Skottke, J., Nötzel, D., Hinkfoth, F., Tikk, K., Daniel-Moreno, A., Ceiler, J., Mercaldo, N., … Steinkraus, B. R. (2022). A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy. Npj Precision Oncology, 6(1), 19.

Rosenberger, A., Muttray, N., Hung, R. J., Christiani, D. C., Caporaso, N. E., Liu, G., Bojesen, S. E., Le Marchand, L., Albanes, D., Aldrich, M. C., Tardon, A., Fernández-Tardón, G., Rennert, G., Field, J. K., Davies, M. P. A., Liloglou, T., Kiemeney, L. A., Lazarus, P., Wendel, B., … Bickeböller, H. (2022). Gene–gene interaction of AhRwith and within the Wntcascade affects susceptibility to lung cancer. European Journal of Medical Research, 27(1), 14.


Kirchner, M., Kluck, K., Brandt, R., Volckmar, A. L., Penzel, R., Kazdal, D., Endris, V., Neumann, O., Seker-Cin, H., Goldschmid, H., Glade, J., Allgäuer, M., Kriegsmann, M., Winter, H., Muley, T., Perner, S., Frost, N., Reck, M., Fröhling, S., … Stenzinger, A. (2021). The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma. ESMO Open, 6(5), 100253.

Mountzios, G., Samantas, E., Senghas, K., Zervas, E., Krisam, J., Samitas, K., Bozorgmehr, F., Kuon, J., Agelaki, S., Baka, S., Athanasiadis, I., Gaissmaier, L., Elshiaty, M., Daniello, L., Christopoulou, A., Pentheroudakis, G., Lianos, E., Linardou, H., Kriegsmann, K., … Christopoulos, P. (2021). Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open, 6(5), 100254.

Troschel, F. M., Jin, Q., Eichhorn, F., Muley, T., Best, T. D., Leppelmann, K. S., Yang, C. F. J., Troschel, A. S., Winter, H., Heußel, C. P., Gaissert, H. A., & Fintelmann, F. J. (2021). Sarcopenia on preoperative chest computed tomography predicts cancer-specific and all-cause mortality following pneumonectomy for lung cancer: A multicenter analysis. Cancer Medicine, 10(19), 6677–6686.

Schamschula, E., Lahnsteiner, A., Assenov, Y., Hagmann, W., Zaborsky, N., Wiederstein, M., Strobl, A., Stanke, F., Muley, T., Plass, C., Tümmler, B., & Risch, A. (2021). Disease-related blood-based differential methylation in cystic fibrosis and its representation in lung cancer revealed a regulatory locus in PKP3 in lung epithelial cells. Epigenetics, 17(8), 837–860.

Khan, M. M., Poeckel, D., Halavatyi, A., Zukowska-Kasprzyk, J., Stein, F., Vappiani, J., Sevin, D. C., Tischer, C., Zinn, N., Eley, J. D., Gudmann, N. S., Muley, T., Winter, H., Fisher, A. J., Nanthakumar, C. B., Bergamini, G., & Pepperkok, R. (2021). An integrated multiomic and quantitative label-free microscopy-based approach to study pro-fibrotic signalling in ex vivo human precision-cut lung slices. European Respiratory Journal, 58(1), 2000221.

Daniello, L., Elshiaty, M., Bozorgmehr, F., Kuon, J., Kazdal, D., Schindler, H., Shah, R., Volckmar, A. L., Lusky, F., Diekmann, L., Liersch, S., Faehling, M., Muley, T., Kriegsmann, M., Benesova, K., Stenzinger, A., Thomas, M., & Christopoulos, P. (2021). Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer. Frontiers in Oncology, 11.

Kriegsmann, K., Zgorzelski, C., Muley, T., Christopoulos, P., Thomas, M., Winter, H., Eichhorn, M., Eichhorn, F., von Winterfeld, M., Herpel, E., Goeppert, B., Stenzinger, A., Herth, F. J. F., Warth, A., & Kriegsmann, M. (2021). Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples. BMC Cancer, 21(1), 486.

Eichhorn, F., Kriegsmann, M., Klotz, L. V., Kriegsmann, K., Muley, T., Zgorzelski, C., Christopoulos, P., Winter, H., & Eichhorn, M. E. (2021). Prognostic impact of pd-l1 expression in pn1 nsclc: A retrospective single-center analysis. Cancers, 13(9), 2046.

Baum, P., Taber, S., Erdmann, S., Muley, T., Kriegsmann, M., Christopoulos, P., Thomas, M., Winter, H., Pfannschmidt, J., & Eichhorn, M. E. (2021). Validation of the t descriptor (Tnm-8) in t3n0 non-small-cell lung cancer patients; a bicentric cohort analysis with arguments for redefinition. Cancers, 13(8), 1812.

Bozorgmehr, F., Kazdal, D., Chung, I., Kirchner, M., Magios, N., Kriegsmann, M., Allgäuer, M., Klotz, L. V., Muley, T., El Shafie, R. A., Fischer, J. R., Faehling, M., Stenzinger, A., Thomas, M., & Christopoulos, P. (2021). De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer. Frontiers in Oncology, 11.

Kazdal, D., Rempel, E., Oliveira, C., Allgäuer, M., Harms, A., Singer, K., Kohlwes, E., Ormanns, S., Fink, L., Kriegsmann, J., Leichsenring, M., Kriegsmann, K., Stögbauer, F., Tavernar, L., Leichsenring, J., Volckmar, A. L., Longuespée, R., Winter, H., Eichhorn, M., … Kriegsmann, M. (2021). Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. Translational Lung Cancer Research, 10(4), 1666–1678.

Magios, N., Bozorgmehr, F., Volckmar, A. L., Kazdal, D., Kirchner, M., Herth, F. J., Heussel, C. P., Eichhorn, F., Meister, M., Muley, T., Elshafie, R. A., Fischer, J. R., Faehling, M., Kriegsmann, M., Schirmacher, P., Bischoff, H., Stenzinger, A., Thomas, M., & Christopoulos, P. (2021). Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer. Therapeutic Advances in Medical Oncology, 13, 175883592199650.

Llamazares-Prada, M., Espinet, E., Mijošek, V., Schwartz, U., Lutsik, P., Tamas, R., Richter, M., Behrendt, A., Pohl, S. T., Benz, N. P., Muley, T., Warth, A., Heußel, C. P., Winter, H., Landry, J. J. M., Herth, F. J. F., Mertens, T. C. J., Karmouty-Quintana, H., Koch, I., … Jurkowska, R. Z. (2021). Versatile workflow for cell type-resolved transcriptional and epigenetic profiles from cryopreserved human lung. JCI Insight, 6(6).

Budczies, J., Kirchner, M., Kluck, K., Kazdal, D., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J., Winter, H., Meister, M., Muley, T., Fröhling, S., Peters, S., Seliger, B., Schirmacher, P., Thomas, M., Christopoulos, P., & Stenzinger, A. (2021). A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. OncoImmunology, 10(1).

Brunn, D., Turkowski, K., Günther, S., Weigert, A., Muley, T., Kriegsmann, M., Winter, H., Dammann, R. H., Stathopoulos, G. T., Thomas, M., Guenther, A., Grimminger, F., Pullamsetti, S. S., Seeger, W., & Savai, R. (2021). Interferon regulatory factor 9 promotes lung cancer progression via regulation of versican. Cancers, 13(2), 1–19.

Shah, R., Klotz, L. V., Chung, I., Feißt, M., Schneider, M. A., Riedel, J., Bischoff, H., Eichhorn, M. E., & Thomas, M. (2021). A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. Clinical Lung Cancer, 22(2), 142–146.

Veith, C., Hristova, M., Danyal, K., Habibovic, A., Dustin, C. M., McDonough, J. E., Vanaudenaerde, B. M., Kreuter, M., Schneider, M. A., Kahn, N., Van Schooten, F. J., Boots, A. W., & Van Der Vliet, A. (2021). Profibrotic epithelial TGF-β1 signaling involves NOX4-mitochondria cross talk and redox-mediated activation of the tyrosine kinase FYN. American Journal of Physiology - Lung Cellular and Molecular Physiology, 320(3), L356–L367.

Christopoulos, P., Bozorgmehr, F., Brückner, L., Chung, I., Krisam, J., Schneider, M. A., Stenzinger, A., Eickhoff, R., Mueller, D. W., & Thomas, M. (2021). Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial. BMC Cancer, 21(1), 743.

Angeles, A. K., Christopoulos, P., Yuan, Z., Bauer, S., Janke, F., Ogrodnik, S. J., Reck, M., Schlesner, M., Meister, M., Schneider, M. A., Dietz, S., Stenzinger, A., Thomas, M., & Sültmann, H. (2021). Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis. Npj Precision Oncology, 5(1), 100.

Trefzer, T., Schneider, M. A., Jechow, K., Chua, L., Muley, T., Winter, H., Kriegsmann, M., Meister, M., Eils, R., & Conrad, C. (2021). Intratumoural heterogeneity and immune modulation in lung adenocarcinoma of female smokers and never smokers. BioRxiv, 82(17), 2021.05.18.444603.

Schamschula, E., Lahnsteiner, A., Assenov, Y., Hagmann, W., Zaborsky, N., Wiederstein, M., Strobl, A., Stanke, F., Muley, T., Plass, C., Tümmler, B., & Risch, A. (2021). Disease-related blood-based differential methylation in cystic fibrosis and its representation in lung cancer revealed a regulatory locus in PKP3 in lung epithelial cells. Epigenetics, 17(8), 837–860.


Janke, F., Bozorgmehr, F., Wrenger, S., Dietz, S., Heussel, C. P., Heussel, G., Silva, C. F., Rheinheimer, S., Feisst, M., Thomas, M., Golpon, H., Günther, A., Sültmann, H., Muley, T., Janciauskiene, S., Meister, M., & Schneider, M. A. (2020). Novel liquid biomarker panels for a very early response capturing of nsclc therapies in advanced stages. Cancers, 12(4), 954.

Lukassen, S., Chua, R. L., Trefzer, T., Kahn, N. C., Schneider, M. A., Muley, T., Winter, H., Meister, M., Veith, C., Boots, A. W., Hennig, B. P., Kreuter, M., Conrad, C., & Eils, R. (2020). SARS ‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells . The EMBO Journal, 39(10).

Turkowski, K., Herzberg, F., Günther, S., Brunn, D., Weigert, A., Meister, M., Muley, T., Kriegsmann, M., Schneider, M. A., Winter, H., Thomas, M., Grimminger, F., Seeger, W., Savai Pullamsetti, S., & Savai, R. (2020). Fibroblast Growth Factor-14 Acts as Tumor Suppressor in Lung Adenocarcinomas. Cells, 9(8), 1755.

Wessels, S., Muley, T., Christopoulos, P., Meister, M., Heinzmann-Groth, I., Warth, A., Herpel, E., Hummler, S., Klingmüller, U., Kuon, J., Heussel, C. P., Eberhardt, R., Herth, F. J. F., Winter, H., Bischoff, H., Stenzinger, A., Reck, M., Huber, R. M., Thomas, M., & Schneider, M. A. (2020). Comprehensive serial biobanking in advanced NSCLC: Feasibility, challenges and perspectives. Translational Lung Cancer Research, 9(4), 1000–1014.

Küster, M. M., Schneider, M. A., Richter, A. M., Richtmann, S., Winter, H., Kriegsmann, M., Pullamsetti, S. S., Stiewe, T., Savai, R., Muley, T., & Dammann, R. H. (2020). Epigenetic inactivation of the tumor suppressor IRX1 occurs frequently in lung adenocarcinoma and its silencing is associated with impaired prognosis. Cancers, 12(12), 1–20.

Dietz, S., Christopoulos, P., Yuan, Z., Angeles, A. K., Gu, L., Volckmar, A. L., Ogrodnik, S. J., Janke, F., Fratte, C. D., Zemojtel, T., Schneider, M. A., Kazdal, D., Endris, V., Meister, M., Muley, T., Cecchin, E., Reck, M., Schlesner, M., Thomas, M., … Sültmann, H. (2020). Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA. EBioMedicine, 62, 103103.

Kim-Wanner, S. Z., Assenov, Y., Nair, M. B., Weichenhan, D., Benner, A., Becker, N., Landwehr, K., Kuner, R., Sültmann, H., Esteller, M., Koch, I., Lindner, M., Meister, M., Thomas, M., Bieg, M., Klingmüller, U., Schlesner, M., Warth, A., Brors, B., … Muley, T. (2020). Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long Noncoding RNA PLUT: An Exploratory Study. Journal of Thoracic Oncology, 15(8), 1338–1350.

Kriegsmann, K., Zgorzelski, C., Muley, T., Christopoulos, P., von Winterfeld, M., Herpel, E., Goeppert, B., Mechtersheimer, G., Sinn, P., Stenzinger, A., Schirmacher, P., Winter, H., Eichinger, M., Warth, A., & Kriegsmann, M. (2020). Immunohistological expression of oestrogen receptor, progesterone receptor, mammaglobin, human epidermal growth factor receptor 2 and GATA-binding protein 3 in non-small-cell lung cancer. Histopathology, 77(6), 900–914.

Safi, S., Yamauchi, Y., Hoffmann, H., Weichert, W., Jost, P. J., Winter, H., Muley, T., & Beckhove, P. (2020). Circulating interleukin-4 is associated with a systemic t cell response against tumor-associated antigens in treatment-naïve patients with resectable non-small-cell lung cancer. Cancers, 12(12), 1–20.

Muley, T., Zhang, X., Holdenrieder, S., Korse, C. M., Zhi, X. Y., Molina, R., Liu, Z., Hartmann, G., van den Heuvel, M. M., Qian, K., Marrades, R., Engel, C., He, Y., Wehnl, B., Dayyani, F., & Herth, F. (2020). A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test. Tumor Biology, 42(9), 101042832095860.

Kriegsmann, M., Zgorzelski, C., Casadonte, R., Schwamborn, K., Muley, T., Winter, H., Eichhorn, M., Eichhorn, F., Warth, A., Deininger, S. O., Christopoulos, P., Thomas, M., Longerich, T., Stenzinger, A., Weichert, W., Müller-Tidow, C., Kriegsmann, J., Schirmacher, P., & Kriegsmann, K. (2020). Mass spectrometry imaging for reliable and fast classification of non-small cell lung cancer subtypes. Cancers, 12(9), 1–14.

Kriegsmann, M., Haag, C., Weis, C. A., Steinbuss, G., Warth, A., Zgorzelski, C., Muley, T., Winter, H., Eichhorn, M. E., Eichhorn, F., Kriegsmann, J., Christopolous, P., Thomas, M., Witzens-Harig, M., Sinn, P., von Winterfeld, M., Heussel, C. P., Herth, F. J. F., Klauschen, F., … Kriegsmann, K. (2020). Deep learning for the classification of small-cell and non-small-cell lung cancer. Cancers, 12(6), 1–15.

Weber, R., Meister, M., Muley, T., Thomas, M., Sültmann, H., Warth, A., Winter, H., Herth, F. J. F., & Schneider, M. A. (2019). Pathways regulating the expression of the immunomodulatory protein glycodelin in non-small cell lung cancer. International Journal of Oncology, 54(2), 515–526.

Fakhiri, J., Schneider, M. A., Puschhof, J., Stanifer, M., Schildgen, V., Holderbach, S., Voss, Y., El Andari, J., Schildgen, O., Boulant, S., Meister, M., Clevers, H., Yan, Z., Qiu, J., & Grimm, D. (2019). Novel Chimeric Gene Therapy Vectors Based on Adeno-Associated Virus and Four Different Mammalian Bocaviruses. Molecular Therapy - Methods and Clinical Development, 12, 202–222.

Muley, T., He, Y., Rolny, V., Wehnl, B., Escherich, A., Warth, A., Stolp, C., Schneider, M. A., Meister, M., Herth, F. J., & Dayyani, F. (2019). Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung. Lung Cancer, 130, 194–200.

Richtmann, S., Wilkens, D., Warth, A., Lasitschka, F., Winter, H., Christopoulos, P., Herth, F. J. F., Muley, T., Meister, M., & Schneider, M. A. (2019). FAM83A and FAM83B as prognostic biomarkers and potential new therapeutic targets in NSCLC. Cancers, 11(5), 652.

Janciauskiene, S., Ercetin, E., Richtmann, S., Delgado, B. M., Gomez-Mariano, G., Wrenger, S., Korenbaum, E., Liu, B., Deluca, D., Kühnel, M. P., Jonigk, D., Yuskaeva, K., Warth, A., Muley, T., Winter, H., Meister, M., Welte, T., & Schneider, M. A. (2019). Clinical significance of serpina1 gene and its encoded alpha1-antitrypsin protein in nsclc. Cancers, 11(9), 1306.

Dietz, S., Christopoulos, P., Gu, L., Volckmar, A. L., Endris, V., Yuan, Z., Ogrodnik, S. J., Zemojtel, T., Heussel, C. P., Schneider, M. A., Meister, M., Muley, T., Reck, M., Schlesner, M., Thomas, M., Stenzinger, A., & Sültmann, H. (2019). Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1-ALKrearranged lung cancer. Cold Spring Harbor Molecular Case Studies, 5(6), a004630.

Kazdal D, Harms A, Endris V, Penzel R, Oliveira C, Kriegsmann M, Longuespée R, Winter H, Schneider MA, Muley T, Pfarr N, Weichert W, Stenzinger A, Warth A. Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations. Lung Cancer. 2018 Dec;126:80-88.

Roth A, Boulay K, Groß M, Polycarpou-Schwarz M, Mallette FA, Regnier M, Bida O, Ginsberg D, Warth A, Schnabel PA, Muley T, Meister M, Zabeck H, Hoffmann H, Diederichs S. Restoring LINC00673 expression triggers cellular senescence in lung cancer. RNA Biol. 2018 Nov 30. doi: 10.1080/15476286.2018.1553481. [Epub ahead of print]

Marc A. SchneiderThomas MuleyRebecca WeberSabine WesselsMichael ThomasFelix J. F. HerthNicolas C. KahnRalf EberhardtHauke WinterGudula HeusselArne WarthChristel Herold-Mende and Michael Meister. Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC Cancers 2018, 10(12), 486; doi: 10.3390/cancers10120486

Thomas Muley, Vinzent Rolny, Ying He, Birgit Wehnl, Achim Escherich, Arne Warth, Christa Stolp, Marc A. Schneider, Hendrik Dienemann, Michael Meister, Felix J. Herth, Farshid Dayyani. The Combination of the Blood Based Tumor Biomarkers Cytokeratin 19 Fragments (CYFRA 21-1) and Carcinoembryonic Antigen (CEA) as a Potential Predictor of Benefit from Adjuvant Chemotherapy in Early Stage Squamous Cell Carcinoma of the Lung (SCC). Lung Cancer 2018, 120: 46-53

Safi S, Op den Winkel J, Kramer S, Keast T, Wibowo H, Muley T, Herth FJF. A new bronchoscopic catheter for the transbronchial ablation of pulmonary nodules.  Lung Cancer. 2018 Oct;124:125-129.

Zabeck H, Dienemann H, Hoffmann H, Pfannschmidt J, Warth A, Schnabel PA, Muley T, Meister M, Sültmann H, Fröhlich H, Kuner R, Lasitschka F. Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma.  PLoS One. 2018 Oct 23;13(10):e0206132. doi: 10.1371/journal.pone.0206132. eCollection 2018

Kriegsmann K, Zgorzelski C, Kazdal D, Cremer M, Muley T, Winter H, Longuespée R, Kriegsmann J, Warth A, Kriegsmann M. Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56. Appl Immunohistochem Mol Morphol. 2018 Oct 24. doi: 10.1097/PAI.0000000000000715. [Epub ahead of print]

Kriegsmann M, Kriegsmann K, Harms A, Longuespée R, Zgorzelski C, Leichsenring J, Muley T, Winter H, Kazdal D, Goeppert B, Warth A. Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer. Diagn Pathol. 2018 Sep 11;13(1):68. doi: 10.1186/s13000-018-0751-7.

Ji X, Bossé Y, Landi MT, Gui J, Xiao X, Qian D, Joubert P, Lamontagne M, Li Y, Gorlov I, de Biasi M, Han Y, Gorlova O, Hung RJ, Wu X, McKay J, Zong X, Carreras-Torres R, Christiani DC, Caporaso N, Johansson M, Liu G, Bojesen SE, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Chen C, Teare MD, Field JK, Kiemeney LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leighl N, Johansen JS, Mellemgaard A, Saliba W, Haiman C, Wilkens L, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden EHFM, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty J, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Manz J, Muley T, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd F, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Koh WP, Gao YT, Houlston R, McLaughlin J, Stevens V, Nickle DC, Obeidat M, Timens W, Zhu B, Song L, Artigas MS, Tobin MD, Wain LV, Gu F, Byun J, Kamal A, Zhu D, Tyndale RF, Wei WQ, Chanock S, Brennan P, Amos CI. Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun. 2018 Aug 13;9(1):3221. doi: 10.1038/s41467-018-05074-y.

Christopoulos P, Chung I, Bozorgmehr F, Muley T, Meister M, Kobinger S, Marx A, Thomas M, Winter H, Herpel E, Rieker RJ, Fisch P, Grosch H. Deficient CD247 expression is a typical histopathologic characteristic of thymomas with cortical features. Histopathology. 2018; 73:1040-1043    doi: 10.1111/his.13724. [Epub ahead of print

Dvornikov D, Schneider MA, Ohse S, Szczygieł M, Titkova I, Rosenblatt M, Muley T, Warth A, Herth FJ, Dienemann H, Thomas M, Timmer J, Schilling M, Busch H, Boerries M, Meister M, Klingmüller U. Expression ratio of the TGFβ-inducible gene MYO10 is prognostic for overall survival of squamous cell lung cancer patients and predicts chemotherapy response. Sci Rep. 2018 Jun 22;8(1):9517. doi: 10.1038/s41598-018-27912-1

Rosenberger A, Hung RJ, Christiani DC, Caporaso NE, Liu G, Bojesen SE, Le Marchand L, Haiman CA, Albanes D, Aldrich MC, Tardon A, Fernández-Tardón G, Rennert G, Field JK, Kiemeney B, Lazarus P, Haugen A, Zienolddiny S, Lam S, Schabath MB, Andrew AS, Brunnsstöm H, Goodman GE, Doherty JA, Chen C, Teare MD, Wichmann HE, Manz J, Risch A, Muley TR, Johansson M, Brennan P, Landi MT, Amos CI, Pesch B, Johnen G, Brüning T, Bickeböller H, Gomolka M. Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health. 2018; 91:937-950 doi: 10.1007/s00420-018-1334-3. [Epub ahead of print

Melnik S, Dvornikov D, Müller-Decker K, Depner S, Stannek P, Meister M, Warth A, Thomas M, Muley T, Risch A, Plass C, Klingmüller U, Niehrs C, Glinka A. Cancer cell specific inhibition of Wnt/β-catenin signaling by forced intracellular acidification. Cell Discov. 2018 Jul 3;4:37. doi: 10.1038/s41421-018-0033-2. eCollection 2018

Kahn N, Rossler AK, Hornemann K, Muley T, Grünig E, Schmidt W, Herth FJF, Kreuter M. C-proSP-B: A Possible Biomarker for Pulmonary Diseases? Respiration. 2018 May 15:1-10. doi: 10.1159/000488245.

Muley T, Rolny V, He Y, Wehnl B, Escherich A, Warth A, Stolp C, Schneider MA, Dienemann H, Meister M, Herth FJ, Dayyani F. The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC). Lung Cancer. 2018 Jun;120:46-53. doi: 10.1016/j.lungcan.2018.03.015. Epub 2018 Mar 17

Christopoulos P, Schneider MA, Bozorgmehr F, Kuon J, Engel-Riedel W, Kollmeier J, Baum V, Muley T, Schnabel PA, Bischoff H, Grohé C, Serke M, Thomas M, Fisch P, Meister M. 
Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance.  Lung Cancer. 2018 May;119:48-55. doi: 10.1016/j.lungcan.2018.03.002. Epub 2018 Mar 6.

Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, Warth A, Eichhorn M, Muley T, Herth FJF, Dienemann H, Platten M, Beckhove P, Utikal J, Hoffmann H, Umansky V. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-small-cell Lung Cancer. Am J Respir Crit Care Med. 2018; 198:777-787 Apr 4. doi: 10.1164/rccm.201708-1707OC. [Epub ahead of print]

Eichhorn F, Harms A, Warth A, Muley T, Winter H, Eichhorn ME. PD-L1 expression in large cell neuroendocrine carcinoma of the lung. Lung Cancer. 2018 Apr; 118:76-82.

Kriegsmann M, Harms A, Kazdal D, Fischer S, Stenzinger A, Leichsenring J, Penzel R, Longuespée R, Kriegsmann K, Muley T, Safi S, Warth A. Analysis of the proliferative activity in lung adenocarcinomas with specific driver mutations. Pathol Res Pract. 2018 Mar;214(3):408-416.

Kriegsmann M, Harms A, Longuespée R, Muley T, Winter H, Kriegsmann K, Kazdal D, Goeppert B, Pathil A, Warth A. Role of conventional immunomarkers, HNF4-α and SATB2, in the differential diagnosis of pulmonary and colorectal adenocarcinomas. Histopathology. 2018 May;72(6):997-1006. doi: 10.1111/his.13455. Epub 2018 Feb 20

Radovich MPickering CRFelau 3, Ha GZhang HJo HHoadley KAAnur PZhang JMcLellan MBowlby RMatthew TDanilova LHegde AMKim JLeiserson MDMSethi GLu CRyan MSu XCherniack ADRobertson GAkbani RSpellman PWeinstein JNHayes DNRaphael BLichtenberg TLeraas KZenklusen JCCancer Genome Atlas NetworkFujimoto JScapulatempo-Neto CMoreira ALHwang DHuang JMarino MKorst RGiaccone GGokmen-Polar YBadve SRajan AStröbel PGirard NTsao MSMarx ATsao ASLoehrer PJ.
Collaborators (141)
Ally AAppelbaum ELAuman JTBalasundaram MBalu SBehera MBeroukhim RBerrios MBlandino GBodenheimer TBootwalla MSBowen JBrooks DCarcano FMCarlsen RCarvalho ALCastro PChalabreysse LChin LCho JChoe GChuah EChudamani SCibulskis CCope LCordes MGCrain DCurley EDefreitas TDemchok JADetterbeck FDhalla NDienemann HEdenfield WJFacciolo FFerguson MLFrazer SFronick CCFulton LAFulton RSGabriel SBGardner JGastier-Foster JMGehlenborg NGerken MGetz GHeiman DIHobensack SHolbrook AHolt RAHoyle APHutter CMIttmann MJefferys SRJones CDJones SJMKasaian KKim JKimes PKLai PHLaird PWLawrence MSLin PLiu JLolla LLu YMa YMaglinte DTMallery DMardis ERMarra MAMartin JMayo MMeier SMeister MMeng SMeyerson MMieczkowski PAMiller CAMills GBMoore RAMorris SMose LEMuley TMungall AJMungall KNaresh RNewton YNoble MSOwonikoko TParker JSPaulaskis JPenny RPerou CMPerrin CPihl TRadenbaugh ARamalingam SRamirez NRieker RRoach JSadeghi SSaksena GSchein JESchmidt HKSchumacher SEShelton CShelton TShi YShih JSica GSilveira HCSSimons JVSipahimalani PSkelly TSofia HJSoloway MGStuart JSun QTam ATan DTarnuzzer RThiessen NVan Den Berg DJVasef MAVeluvolu UVoet DWalter VWan YWang ZWarth AWeis CAWeisenberger DJWilkerson MDWise LWong TWu HTWu YYang LZhang JZmuda E. The Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 2018 Feb 12;33(2):244-258.e10. doi: 10.1016/j.ccell.2018.01.003.

Gonzalez-Vallinas M, Rodriguez-Paredes M, Albrecht M, Sticht C, Stichel D, Gutekunst J, Pitea A, Sass S, Sánchez-Rivera FJ, Bermejo JL, Schmitt J, De La Torre C, Warth A, Theis F, Mueller N, Gretz N, Muley T, Meister M, Tschaharganeh DF, Schirmacher P, Matthäus F, Breuhahn K. Epigenetically Regulated Chromosome 14q32 miRNA Cluster Induces Metastasis and Predicts Poor Prognosis in Lung Adenocarcinoma Patients. Mol Cancer Res. 2018; 16:390-402  pii: molcanres.0334.2017. doi: 10.1158/1541-7786.MCR-17-0334. [Epub ahead of print]

Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, Ristau J, Buchhalter I, Penzel R, Herth FJ, Heussel CP, Eichhorn M, Muley T, Meister M, Fischer JR, Rieken S, Warth A, Bischoff H, Schirmacher P, Stenzinger A, Thomas M. EML4-ALK fusion variant V3 is a high-risk feature conferring  accelerated metastatic spread, early treatment failure and worse overall survival in ALK(+). non-small cell lung cancer. Int J Cancer. 2018;   142:2589-2598  doi: 10.1002/ijc.31275. [Epub ahead of print] PubMed PMID: 29363116.

Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, Bubendorf L, Speel EJ,  Marchetti A, Nonaka D, Monkhorst K, Hager H, Martorell M, Sejda A, Cheney R, Hernandez-Losa J, Verbeken E, Weder W, Savic S, Di Lorito A, Navarro A, Felip E, Warth A, Baas P, Meldgaard P, Blackhall F, Dingemans AM, Dienemann H, Dziadziuszko R, Vansteenkiste J, O'Brien C, Geiger T, Sherlock J, Schageman J, Dafni U, Kammler R, Kerr K, Thunnissen E, Stahel R, Peters S; European Thoracic Oncology Platform Lungscape Consortium. Evaluation of NGS and RT-PCR Methods for  ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic  Oncology Platform Lungscape Project. J Thorac Oncol. 2018 Mar;13(3):413-425. doi: 10.1016/j.jtho.2017.11.117. Epub 2017 Nov 27. PubMed PMID: 29191776.

Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S; ETOP Lungscape  Consortium. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project. Ann Oncol. 2018 Jan 1;29(1):200-208. doi: 10.1093/annonc/mdx629. PubMed PMID: 29186353.

Yamauchi Y, Safi S, Muley T, Warth A, Herth FJF, Dienemann H, Hoffmann H, Eichhorn ME. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients. Lung Cancer. 2017 Dec;114:62-67. doi: 10.1016/j.lungcan.2017.11.002. Epub 2017 Nov 3.  PubMed PMID: 29173768.

Kriegsmann M, Harms A, Longuespée R, Muley T, Winter H, Kriegsmann K, Kazdal D, Goeppert B, Pathil A, Warth A. Role of Conventional Immunomarkers, HNF4-a, and SATB2 in the Differential Diagnosis of Pulmonary and Colorectal Adenocarcinomas. Histopathology. 2017 Dec 15. doi: 10.1111/his.13455. [Epub ahead of print]

Li Y, Xiao X, Han Y, Gorlova O, Qian D, Leighl N, Johansen JS, Barnett M, Chen C, Goodman G, Cox A, Taylor F, Woll P, Wichmann HE, Manz J, Muley T, Risch A, Rosenberger A, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Houlston R, Artigas MS, Grankvist K, Johansson M, Shepherd FA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Liu G, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeney LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Bertazzi PA, Pesatori AC, Christiani DC, Caporaso N, Johansson M, McKay JD, Brennan P, Hung RJ, Amos CI. Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population. Carcinogenesis. 2017 Oct 20. doi: 10.1093/carcin/bgx113. [Epub ahead of print

Schmidt LH, Stucke-Ring J, Brand C, Schliemann C, Harrach S, Muley T, Herpel E, Kessler T, Mohr M, Görlich D, Kreuter M, Lenz G, Wardelmann E, Thomas M, Berdel WE, Schwöppe C, Hartmann W. CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer.Lung Cancer. 2017 Nov;113:121-127. doi: 10.1016/j.lungcan.2017.09.013. Epub 2017 Sep 22.

Costa da Silva M, Breckwoldt MO, Vinchi F, Correia MP, Stojanovic A, Thielmann CM, Meister M, Muley T, Warth A, Platten M, Hentze MW, Cerwenka A, Muckenthaler MU. Iron Induces Anti-tumor Activity in Tumor-Associated Macrophages. Front Immunol. 2017 Nov 8;8:1479. doi: 10.3389/fimmu.2017.01479. eCollection 2017

K.M. Kerr, U. Dafni, K. Schulze, E. Thunnissen, L. Bubendorf, H. Hager, S. Finn, W. Biernat, L. Vliegen, J. H. Losa, A. Marchetti, R. Cheney, A. Warth, E-J. Speel, F. Blackhall, K. Monkhorst, E. Jantus Lewintre, V. Tischler, C. Clark, J. Bertran-Alamillo, P. Meldgaard, K. Gately, A. Wrona, P. Vandenberghe, E. Felip, G. De Luca, S. Savic, T. Muley, E. F. Smit, A-M. C. Dingemans, L. Priest, P. Baas, C. Camps, W. Weder, V. Polydoropoulou, T.R. Geiger, R. Kammler, T. Sumiyoshi, M. A. Molina, D. S. Shames, R.A. Stahel, S. Peters, for the ETOP Lungscape Consortium. Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from  the ETOP Lungscape Project. Annals of Oncology 2017, MDX629

Zhao J, Dinkel J, Warth A, Penzel R, Reinmuth N, Schnabel P, Muley T, Meister M, Zabeck H, Steins M, Yang JY, Zhou Q, Schlemmer HP, Herth FJF, Kauczor HU, Heussel CP. CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation. PLoS One. 2017 Sep 26;12(9):e0182741. doi: 10.1371/journal.pone.0182741. eCollection 2017

Kazdal D, Harms A, Endris V, Penzel R, Kriegsmann M, Eichhorn F, Muley T, Stenzinger A, Pfarr N, Weichert W, Warth A. Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer. Br J Cancer. 2017 May 30. doi: 10.1038/bjc.2017.155. [Epub ahead of print]

McKay JD, Hung RJ, Han Y, Zong X, Carreras-Torres R, Christiani DC, Caporaso NE, Johansson M, Xiao X, Li Y, Byun J, Dunning A, Pooley KA, Qian DC, Ji X, Liu G, Timofeeva MN, Bojesen SE, Wu X, Le Marchand L, Albanes D, Bickeböller H, Aldrich MC, Bush WS, Tardon A, Rennert G, Teare MD, Field JK, Kiemeney LA, Lazarus P, Haugen A, Lam S, Schabath MB, Andrew AS, Shen H, Hong YC, Yuan JM, Bertazzi PA, Pesatori AC, Ye Y, Diao N, Su L, Zhang R, Brhane Y, Leighl N, Johansen JS, Mellemgaard A, Saliba W, Haiman CA, Wilkens LR, Fernandez-Somoano A, Fernandez-Tardon G, van der Heijden HFM, Kim JH, Dai J, Hu Z, Davies MPA, Marcus MW, Brunnström H, Manjer J, Melander O, Muller DC, Overvad K, Trichopoulou A, Tumino R, Doherty JA, Barnett MP, Chen C, Goodman GE, Cox A, Taylor F, Woll P, Brüske I, Wichmann HE, Manz J, Muley TR, Risch A, Rosenberger A, Grankvist K, Johansson M, Shepherd FA, Tsao MS, Arnold SM, Haura EB, Bolca C, Holcatova I, Janout V, Kontic M, Lissowska J, Mukeria A, Ognjanovic S, Orlowski TM, Scelo G, Swiatkowska B, Zaridze D, Bakke P, Skaug V, Zienolddiny S, Duell EJ, Butler LM, Koh WP, Gao YT, Houlston RS, McLaughlin J, Stevens VL, Joubert P, Lamontagne M, Nickle DC, Obeidat M, Timens W, Zhu B, Song L, Kachuri L, Artigas MS, Tobin MD, Wain LV; SpiroMeta Consortium, Rafnar T, Thorgeirsson TE, Reginsson GW, Stefansson K, Hancock DB, Bierut LJ, Spitz MR, Gaddis NC, Lutz SM, Gu F, Johnson EO, Kamal A, Pikielny C, Zhu D, Lindströem S, Jiang X, Tyndale RF, Chenevix-Trench G, Beesley J, Bossé Y, Chanock S, Brennan P, Landi MT, Amos CI. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat Genet. 2017 Jun 12. doi: 10.1038/ng.3892. [Epub ahead of print]

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

Guo M, Tomoshige K, Meister M, Muley T, Fukazawa T, Tsuchiya T, Karns R, Warth A, Fink-Baldauf IM, Nagayasu T, Naomoto Y, Xu Y, Mall MA, Maeda Y. Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Mol Med. 2017 Mar 2. pii: e201606711. doi: 10.15252/emmm.201606711. [Epub ahead of print]

Nattenmüller J, Wochner R, Muley T, Steins M, Hummler S, Teucher B, Wiskemann J, Kauczor HU, Wielpütz MO, Heussel CP. Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after  First-Line-Chemotherapy in Lung Cancer Patients. PLoS One. 2017 Jan 20;12(1):e0169136. doi: 10.1371/journal.pone.0169136.

Schneider MA, Christopoulos P, Muley T, Warth A, Klingmueller U, Thomas M, Herth FJ, Dienemann H, Mueller NS, Theis F, Meister M. AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients. Int J Oncol. 2017 Feb;50(2):365-372. doi: 10.3892/ijo.2017.3834.

Herpel E, Rieker RJ, Dienemann H, Muley T, Meister M, Hartmann A, Warth A, Agaimy A. SMARCA4 and SMARCA2 deficiency in non-small cell lung cancer: immunohistochemical survey of 316 consecutive specimens. Ann Diagn Pathol. 2017 Feb; 26:47-51.

Pecqueux M, Liebetrau I, Werft W, Dienemann H, Muley T, Pfannschmidt J, Müssle B, Rahbari N, Schölch S, Büchler MW, Weitz J, Reissfelder C, Kahlert C. A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival. Int J Mol Sci. 2016 Oct 21;17(10). pii: E1755. 

Schneider MA, Muley T, Kahn NC, Warth A, Thomas M, Herth FJ, Dienemann H, Meister M. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.Oncotarget. 2016 Oct 4. doi: 10.18632/oncotarget.12474.

Riediger AL, Dietz S, Schirmer U, Meister M, Heinzmann-Groth I, Schneider M, Muley T, Thomas M, Sültmann H. Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients. Sci Rep. 2016 Sep 19;6:33505. doi: 10.1038/srep33505.

Firnkorn D, Merker S, Ganzinger M, Muley T, Knaup P.Unlocking Data for Statistical Analyses and Data Mining: Generic Case Extraction of Clinical Items from i2b2 and tranSMART.  Stud Health Technol Inform. 2016;228:567-71

Dietz S, Schirmer U, Mercé C, von Bubnoff N, Dahl E, Meister M, Muley T, Thomas M, Sültmann H. Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients. PLoS One. 2016,11(8):e0161012.

Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN, Verhaak RG, Wu CJ, Hammerman PS, Cherniack AD, Getz G; Cancer Genome Atlas Research Network, Artyomov MN, Schreiber R, Govindan R, Meyerson M. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016 Jun;48(6):607-16

M. A. Schneider N. C. Kahn, T. Muley, M. Meister, A. Warth, M. Thomas, F. J. F. Herth, H. Dienemann, C. P. Heußel, P. S. van de Weyer Metastasiertes Mukoepidermoidkarzinom der Lunge - Glycodelin als Verlaufsmarker. Journal Onkologie 2016, 3: 184-187

T. Muley, FJF Herth Stellenwert der In-vitro-Diagnostik beim Lungenkrebs. Roche, Diagnostik im Dialog 49 04/2016

Warth A, Muley T, Harms A, Hoffmann H, Dienemann H, Schirmacher P, Weichert W. Clinical Relevance of Different Papillary Growth Patterns of Pulmonary Adenocarcinoma. Am J Surg Pathol. 2016 Feb 26.

Warth A, Endris V, Stenzinger A, Penzel R, Harms A, Duell T, Abdollahi A, Lindner M, Schirmacher P, Muley T, Dienemann H, Fink L, Morresi-Hauf A, Pfarr N, Weichert W. Genetic changes of non-small cell lung cancer under neoadjuvant therapy. Oncotarget. 2016 Apr 20. doi: 10.18632/oncotarget.8858.

Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJ. Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis.  PLoS One. 2016 Mar 29;11(3):e0151425. doi: 10.1371/journal.pone.0151425. eCollection 2016

Marien E, Meister M, Muley T, Gomez Del Pulgar T, Derua R, Spraggins JM, Van de Plas R, Vanderhoydonc F, Machiels J, Binda MM, Dehairs J, Willette Brown J, Hu Y, Dienemann H, Thomas M, Schnabel PA, Caprioli RM, Lacal JC, Waelkens E, Swinnen JV. Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma. Oncotarget. 2016 Feb 3. doi: 10.18632/oncotarget.7179. [Epub ahead of print]

Rieber J, Deeg A, Ullrich E, Foerster R, Bischof M, Warth A, Schnabel PA, Muley T, Kappes J, Heussel CP, Welzel T, Thomas M, Steins M, Dienemann H, Debus J, Hoffmann H, Rieken S. Outcome and prognostic factors of postoperative radiation therapy (PORT) after incomplete resection of non-small cell lung cancer (NSCLC). Lung Cancer. 2016 Jan;91:41-7.

Kreuter M, Kirsten D, Bahmer T, Penzel R, Claussen M, Ehlers-Tenenbaum S, Muley T, Palmowski K, Eichinger M, Leider M, Herth FJ, Rabe KF, Bittmann I, Warth A. Screening for Helicobacter pylori in Idiopathic Pulmonary Fibrosis Lung Biopsies. Respiration